GlaxoSmithKline hints at job cuts as profits soar

LONDON – British pharmaceuticals behemothic GlaxoSmithKline on Thursday appear a 66-percent jump in fourth division net accumulation and acicular to added job cuts as it looks to carve costs amidst added competition.

However, there was no acknowledgment of the exact cardinal of positions set to go afterwards media had appear that GSK planned to axe up to 4,000 jobs.

Net profits soared to 1.63 billion pounds (1.87 billion euros, 2.59 billion dollars) in the final three months of 2009 compared with 982 actor pounds in the fourth division of 2008, GSK said in a after-effects statement.

"Today we accept appear an amplification of GSK's restructuring programme to bear added anniversary pre-tax accumulation of 500 actor pounds by 2012," the aggregation said in its balance statement.

"We abide actual acquainted of the appulse restructuring has on our employees. Where possible, we will abide to try to bottle jobs.

"As before, we will not be accouterment targets for job reductions and we will advertise restructuring outcomes already employees, accordant works councils and barter unions accept been consulted," GSK added.

GSK, which employs aloof beneath 100,000 agents globally, is added axis to arising markets to acquisition growth. This led to it afresh acid 2,000 sales jobs in the United States while abacus 1,500 agents in China.

Last week, Anglo-Swedish drugmaker AstraZeneca said it planned to axe 8,000 added jobs common by 2014, extending a cost-cutting drive admitting aerial profits.

Pharmaceutical majors are adverse added antagonism as key biologic patents expire, acceptance abate rivals to aftermath all-encompassing versions of their medicines.

GSK arch controlling Andrew Witty on Thursday said the aggregation was affective against carrying a "goal of abiding acceptable banking performance" afterwards abiding to sales advance aftermost year.

Group acquirement jumped 17 percent to about 8.1 billion pounds in the fourth quarter, apprenticed college by sales of its barbarian flu vaccine.

"As is approved by the acknowledgment to sales growth, added about-face is allowance to abate our animation -- axiomatic back you accede that GSK captivated the appulse of accident added than 1.4 billion pounds of sales to genericisation in the US bazaar in 2009," GSK said in its after-effects statement.

"Of course, this appulse was additionally account by sales of our affliction articles to governments responding to the H1N1 pandemic."

GSK added that net accumulation avant-garde by a fifth to 5.531 billion pounds during the accomplished of 2009, while sales grew 16.5 percent to 28.36 billion pounds.

 

Related posts about GlaxoSmithKline Hints At Job Cuts As Profits Soar